TRBV16

Across TCGA pan-cancer cohorts, TRBV16 RNA is linked to patient survival in 18 of 34 cancer types, making it the most broadly survival-associated TRBV16 data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher TRBV16 RNA is associated with better overall survival. In most high-consensus cancer types, elevated TRBV16 expression acts as an unfavorable survival marker, although some lineages such as STAD and OV show a favorable association.

STAD, KICH, and KIRC are the cancer types where TRBV16 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Tertile	IV	0.728	0.192	.001	117	view →
KICH	DFS	Tertile	All	0.354	0.872	<.001	99	view →
KIRC	OS	Median	All	0.754	0.838	.002	53	view →
ACC	OS	Tertile	All	0.123	0.705	<.001	48	view →
LUSC	OS	Tertile	IV	0.001	0.673	.014	36	view →
MESO	OS	Median	IV	0.197	0.726	<.001	30	view →
OV	OS	Quartile	III,IV	0.413	0.329	.029	30	view →
SKCM	OS	Tertile	All	0.420	0.302	.006	29	view →
PAAD	OS	Tertile	All	0.267	0.510	.024	24	view →
THYM	OS	Median	All	1.000	0.743	.001	19	view →
KIRP	DFS	Tertile	III,IV	0.040	0.691	<.001	18	view →
LUAD	DFS	Tertile	IV	0.632	0.929	.035	18	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 18 lineages.

TRBV16–STAD (OS)

Open the STAD breakdown →